Pfizer grabs leg up in pursuit of rare disease drug win

The FDA has given pharma giant Pfizer ($PFE) a fast-track review of its drug tafamidis meglumine for treating the rare disease known as transthyretin familial amyloid polyneuropathy, meaning the agency is set to decide on the drugmaker's application for approval by June, The Wall Street Journal reported. The fast-track designation boosts Pfizer's move into the rare disease drug segment, which has attracted lots of attention from the company and its Big Pharma counterparts because of its blockbuster prospects. Pfizer picked up tafamidis meglumine via its FoldRx buyout in 2010. Report

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.